Tom 6, Nr 1 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-05-12
Wyświetlenia strony 3814
Wyświetlenia/pobrania artykułu 570
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Postępowanie w raku trzonu macicy z uwzględnieniem klasyfikacji molekularnej — zalecenia ESGO/ESTRO/ESP 2020

Szymon Piątek1, Grzegorz Szewczyk23, Katarzyna Jalinik1, Piotr Sobiczewski1, Mariusz Bidziński1
Ginekologia i Perinatologia Praktyczna 2021;6(1):1-8.

Streszczenie

Na początku lat 80. XX wieku Bokhman przedstawił podział raka trzonu macicy na 2 typy: endometriodny i nieendometrioidny. Chociaż zarówno ginekolodzy, jak i patolodzy w dalszym ciągu stosują go jeszcze w praktyce klinicznej, to ma on już znaczenie historyczne. W minionej dekadzie dokonał się ogromny postęp w diagnostyce raka trzonu macicy poprzez wprowadzenie metod molekularnych oraz immunohistochemicznych. Doprowadziło to do wyodrębnienia 5 nowych typów raka trzonu macicy (ultramutated, hypermutated, high copy number, low copy number, multiple classifier) o odmiennym przebiegu klinicznym oraz różnym rokowaniu. W artykule przedstawiono zalecenia postępowania ESGO/ESTRO/ESP 2020 w raku trzonu macicy z uwzględnieniem nowej klasyfikacji molekularnej.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
  2. Ryan NAJ, Glaire MA, Blake D, et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019; 21(10): 2167–2180.
  3. Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019; 38 Suppl 1: S114–S122.
  4. Mills AM, Liou S, Ford JM, et al. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol. 2014; 38(11): 1501–1509.
  5. Mojtahed A, Schrijver I, Ford JM, et al. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011; 24(7): 1004–1014.
  6. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009; 33(11): 1639–1645.
  7. Møller P, Seppälä T, Bernstein I, et al. Mallorca Group (http://mallorca-group.eu). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017; 66(3): 464–472.
  8. Stelloo E, Nout RA, Osse EM, et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016; 22(16): 4215–4224.
  9. León-Castillo A, Boer Sde, Powell M, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology. 2020; 38(29): 3388–3397.
  10. Kommoss FKf, Karnezis AN, Kommoss F, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018; 119(4): 480–486.
  11. van der Putten LJm, Visser NCm, van de Vijver K, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016; 115(6): 716–724.
  12. Van Gool IC, Stelloo E, Nout RA, et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016; 29(2): 174–181.
  13. WHO Classification of Tumours. Female genital organ tumours, International agency for research on cancer IARC. 5th edn. Lyon. 2020.
  14. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol. 2007; 26(2): 115–123.
  15. Luomaranta A, Leminen A, Loukovaara M. Magnetic resonance imaging in the assessment of high-risk features of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2015; 25(5): 837–842.
  16. Andreano A, Rechichi G, Rebora P, et al. MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. Eur Radiol. 2014; 24(6): 1327–1338.
  17. Alcázar J, Gastón B, Navarro B, et al. Transvaginal ultrasound versus magnetic resonance imaging for preoperative assessment of myometrial infiltration in patients with endometrial cancer: a systematic review and meta-analysis. Journal of Gynecologic Oncology. 2017; 28(6).
  18. Janda M, Gebski V, Davies LC, et al. Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(12): 1224–1233.
  19. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012; 30(7): 695–700.
  20. Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009; 16(12): 3431–3441.
  21. Liu T, Tu H, Li Y, et al. Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis. Ann Surg Oncol. 2019; 26(9): 2933–2942.
  22. Kaban A, Topuz S, Erdem B, et al. Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer. Gynecol Obstet Invest. 2018; 83(5): 482–486.
  23. Joo WD, Schwartz PE, Rutherford TJ, et al. Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis. Ann Surg Oncol. 2015; 22(11): 3695–3700.
  24. Lee B, Suh DH, Kim K, et al. Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Jpn J Clin Oncol. 2016; 46(8): 711–717.
  25. Kim CH, Khoury-Collado F, Barber EL, et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol. 2013; 131(3): 714–719.
  26. Rozenholc A, Samouelian V, Warkus T, et al. Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2019; 153(3): 500–504.
  27. de Boer SM, Powell ME, Mileshkin L, et al. PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(3): 295–309.
  28. Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019; 380(24): 2317–2326.
  29. de Boer SM, Powell ME, Mileshkin L, et al. PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019; 20(9): 1273–1285.
  30. Albeesh R, Turgeon GA, Alfieri J, et al. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. Gynecol Oncol. 2019; 152(1): 26–30.
  31. Scharl S, Papathemelis T, Kronberger K, et al. Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. Arch Gynecol Obstet. 2018; 297(5): 1245–1253.
  32. Bogani G, Cromi A, Serati M, et al. Chemotherapy reduces para-aortic node recurrences in endometrial cancer with positive pelvic and unknown para-aortic nodes. Int J Gynecol Cancer. 2015; 25(2): 263–268.
  33. Rajkumar S, Nath R, Lane G, et al. Advanced stage (IIIC/IV) endometrial cancer: Role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol. 2019; 234: 26–31.
  34. de Lange NM, Ezendam NPM, Kwon JS, et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Curr Oncol. 2019; 26(2): e226–e232.
  35. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer - PubMed. https://pubmed.ncbi.nlm.nih.gov (31 Jan 2021).



Ginekologia i Perinatologia Praktyczna